

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.  
 530 Virginia Road, P.O. Box 9133  
 Concord, MA 01742-9133

Telephone: (978) 341-0036

Facsimile: (978) 341-0136

**FACSIMILE COVER SHEET**

**Examiner:** **Ronald B. Schwadron, Ph.D.** **Group:** 1644

**Date:** August 27, 2003

**FAX RECEIVED**

**Client Code:** 1855.1004-002

**AUG 28 2003**

**Facsimile No.:** 703-308-4242

**GROUP 1600**

**From:** Robert H. Underwood

**Subject:** **Paper:** Reply To Office Communication and Notice To Comply  
 With 37 C.F.R. §§ 1.821-1.825

**Docket No.:** 1855.1004-002

**Applicant:** Michael J. Briskin

**Application No.:** 08/875,849

**Filing Date:** September 8, 1997

Number of pages including this cover sheet: 8

Please confirm receipt of facsimile: Yes        No       

@PP\Desktop\N\QDMA\MS\QDMA\iManage\417118\1

Privileged and Confidential - All information transmitted hereby is intended only for the use of the addressee(s) named above. If the reader of this message is not the intended recipient or the employee or agent responsible for delivering the message to the intended recipient(s), please note that any distribution or copying of this communication is strictly prohibited. Anyone who received this communication in error is asked to notify us immediately by telephone and to destroy the original message or return it to us at the above address via first class mail.

@PFDdesktop\ODMA\MHODMA\Manage;41686\\$;1  
HEW/RHU  
August 27, 2003

PATENT APPLICATION  
Docket No.: 1855.1004-002 (LKS94-04A2)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Michael J. Briskin

Application No.: 08/875,849 Group Art Unit: 1644

Filed: September 8, 1997 Examiner: R. Schwadron

Confirmation No.: 4411

For: MUCOSAL VASCULAR ADDRESSINS AND USES  
THEREOF

FAX RECEIVED

AUG 28 2003

GROUP 1600

CERTIFICATE OF FACSIMILE TRANSMISSION	
I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office	
on <u>August 27, 2003</u>	<u>Shannon Lvis</u>
Date	Signature
<u>Shannon Lvis</u>	
Typed or printed name of person signing certificate	

REPLY TO OFFICE COMMUNICATION AND NOTICE TO COMPLYWITH 37 C.F.R. §§1.821-1.825

Mail Stop Sequence  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This Reply is submitted in response to the Office Communication and Notice to Comply with Requirement for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures attached thereto, mailed from the Patent Office on July 29, 2003. A copy of the Office Communication and Notice to Comply is enclosed.

08/875,849

-2-

The undersigned thanks the Examiner for discussing the Notice to Comply and the rationale described herein by telephone on August 26, 2003.

The Notice to Comply states, “[i]n view of the Request for Correction of Inventorship filed 5/23/2003, a new sequence listing in paper and CRF from [sic] is required deleting former inventors Ringler, Picarella and Newman from section (1)(l).”

Applicant respectfully disagrees that a substitute Sequence Listing must be filed in view of the Request for Correction/Amendment of Inventorship Under 37 C.F.R. § 1.48(b) that was filed on May 23, 2003. 37 C.F.R. § 1.821(e) provides that if the CRF of a new application is identical to the CRF in another application on file in the PTO, reference can be made to the other application and the CRF therein in lieu of filing a new CRF. (37 C.F.R. § 1.821(e).) In order to take advantage of the provisions of § 1.821(e), the applicant must state that the paper or compact disc copy of the Sequence Listing in the new application is identical to the CFR in the other application. The M.P.E.P. further explains that under § 1.821(e), “additional computer readable forms will not be required in derivative or continuing applications if the sequence information is exactly the same, i.e., with no additions or deletions, as that in a parent or previously filed application ....” (M.P.E.P. § 2422.05 at 2400-36.) The M.P.E.P. also instructs that a continuing application can be filed under 37 C.F.R. § 1.53(b) by filing a copy of the prior application (including the Sequence Listing and drawings), including a copy of the signed oath or declaration in the prior application, as filed. (M.P.E.P. § 201.06(c) at 200-36.)

Under the circumstances described in § 1.821(e) and the M.P.E.P., it is apparent that the paper copy or compact disk copy and the CRF of the Sequence Listing in the new application may contain bibliographic data (e.g., Applicant, File Reference, Current Application Number, Current Filing date, Prior Application Number, Prior Application Filing Date) that does not

08/875,849

-3-

correspond to that of the new application. Despite the absence of current bibliographic data, the M.P.E.P. indicates that copies of the paper or compact disk Sequence Listing and CRF from the prior application are acceptable in the new application. There is no requirement in any statute, rule or PTO procedure that a substitute Sequence Listing that contains corrected bibliographic data be provided in such a new application.

The subject application presents a similar situation. Here, the inventorship has been amended to delete persons whose inventions are no longer being claimed. The sequence information in the application is exactly the same now as it was prior to filing the Request for Correction/Amendment of Inventorship Under 37 C.F.R. § 1.48(b). Therefore, the subject application should be treated by the PTO in a manner analogous to the practice under 37 C.F.R. § 1.821(c), and a substitute Sequence Listing should not be required.

In view of the foregoing, and in the spirit of 37 C.F.R. § 1.821(c), it is requested that the holding of noncompliance with 37 C.F.R. §§ 1.821-1.825 be reconsidered and withdrawn.

Respectfully submitted,  
HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Robert H. Underwood  
Robert H. Underwood  
Registration No. 45,170  
Telephone: (978) 341-0036  
Facsimile: (978) 341-0136

Concord, MA 01742-9133  
Date: August 27, 2003



**UNITED STATES PATENT AND TRADEMARK OFFICE**


**DOCKETED**  
 SCD 29 AUG 3  
 SCD 29 JUL 04

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/875,849	09/05/1997	MICHAEL J. BRISKIN	LKS94-04A2	4411
21005	7590	07/29/2003	1855-1004-222	
HAMILTON, BROOK, SMITH & REYNOLDS, P.C. 530 VIRGINIA ROAD P.O. BOX 9133 CONCORD, MA 01742-9133			EXAMINER	SCHWADRON, RONALD B
		ART UNIT	PAPER NUMBER	
		1644		

DATE MAILED: 07/29/2003

Please find below and/or attached an Office communication concerning this application or proceeding.





UNITED STATES  
PATENT AND  
TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY  
AND DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20591  
WWW.USPTO.GOV

DEA/FCO-1994

SERIAL NUMBER	FILED DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
---------------	------------	-----------------------	---------------------

EXAMINER	
ART UNIT	PAPER NUMBER

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application  
Commissioner of Patents

1. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

**In view of the Request for Correction of Inventorship filed 5/23/2003, a new sequence listing in paper and CRF from is required deleting former inventors Ringler, Picarella and Newman from section (1)(i).**

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Any inquiry concerning this communication should be directed to Examiner Ron Schwadron, Ph.D., Art Unit 1644, whose telephone number is (703) 308-4680. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.



RONALD B. SCHWADRON  
PRIMARY EXAMINER  
GROUP 1644

Ron Schwadron, Ph.D.  
Art Unit 1644

Application No.: 08/875849**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."

5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

7. Other: see enclosed communication

**Applicant Must Provide:**

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216  
For CRF Submission Help, call (703) 308-4212  
For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**